US Patent 7,482,377 (Diclofenac + Alkali Bicarbonate Oral Pain Treatment): Scope of Claims and US Patent Landscape
US Patent 7,482,377 is a US method-of-treatment patent focused on oral diclofenac formulations that combine (i) diclofenac in acid and/or alkali salt form with (ii) alkali metal bicarbonates in a high, defined weight range relative to the diclofenac acid form, with additional constraints on maximum diclofenac potassium load and allowable dosage presentation (intact tablet or “powder dissolved or dispersed in water”). The claim set is narrow on key quantitative parameters (20 to 80% by weight bicarbonate/carbonate based on diclofenac acid form; ≤50 mg diclofenac potassium or equivalent where limited) and wide on route (oral) and intended use (treating pain), while leaving substantial room for formulation variants (tablet vs reconstituted/dispersed powder; acid vs sodium/potassium salts; bicarbonate vs carbonate in dependent claims).
What does US 7,482,377 claim cover: diclofenac acid/salt oral pain treatment with alkali bicarbonates?
Core claim 1 scope (method of treating pain). Claim 1 requires all of the following:
- Target condition/indication: “treating pain” in a host in need thereof.
- Route/dosage form: oral administration of a pharmaceutical formulation.
- Drug component: diclofenac in acid and/or salt form.
- Alkali excipient: one or more alkali metal bicarbonates.
- Quantitative limitation: alkali metal bicarbonates are present at 20 to 80% by weight, calculated based on the weight of the acid form of diclofenac.
- Presentation limitation: administered as an intact tablet or as a powder formulation dissolved or dispersed in water.
- Potassium dose cap (tight constraint in claim 1): formulation contains not more than 50 mg of diclofenac potassium (or the equivalent amount of diclofenac in another salt form).
Claim 1’s practical claim boundaries.
- The bicarbonate fraction (20 to 80% w/w relative to diclofenac acid-form weight) is the major technical lever. Many “buffered” diclofenac compositions may miss this exact range.
- The ≤50 mg diclofenac potassium constraint narrows commercial impact if products contain higher diclofenac potassium amounts per dose.
- Allowing both tablet and reconstituted/dispersed powder gives two implementation pathways, but still under a single quantitative framework.
Claim 2 to 7: how far does the patent extend across diclofenac salt choice and dosage form?
- Claim 2: diclofenac is in potassium and/or sodium salt form (excludes other salts not captured by “acid and/or salt form” unless sodium/potassium).
- Claims 3 and 4: specify administration as intact tablet or powder dispersed/dissolved in water, respectively, in the salt-present context of claim 2.
- Claim 5: bicarbonates are potassium and/or sodium bicarbonates (excludes other alkali bicarbonates if not sodium/potassium).
- Claims 6 and 7: reiterate tablet vs powder presentation in the claim 1 framework.
This is standard dependent-claim narrowing: salt identity tightens to sodium/potassium; bicarbonate identity tightens to sodium/potassium; dosage presentation is specified without changing the quantitative range already set in claim 1.
Claim 8: does it claim a pre-dosing manufacturing step?
Claim 8 adds a sequence step:
- providing a unit dose powder of diclofenac in acid and/or salt form, then
- dissolving or dispersing in water before administering
This is meaningful for enforcing against workflows that market a powder to be mixed/reconstituted. It is less relevant for pre-manufactured tablets.
Claim 9: does it cover liquid formulations?
Claim 9 states the formulation is a liquid, still within the claim 1 framework. This expands potential infringement theories beyond tablets and reconstituted powders, even though claim 1 text explicitly limits to “intact tablet” or “powder dissolved/dispersed in water.” In claim construction practice, claim 9 would be read as dependent on claim 1 and thus would inherit claim 1 limitations while substituting “liquid” as the administered formulation form. That can broaden the estate if liquid examples exist in the specification.
Claim 10: does it lock to potassium bicarbonate + diclofenac potassium?
Claim 10 specifies:
- formulation comprises diclofenac potassium and potassium bicarbonate
This is a further narrowing path but can be potent because it aligns closely with a specific marketed composition pattern.
How does Claim 11 differ: does it claim a 50 mg diclofenac potassium formulation?
Claim 11 is structurally similar to claim 1 but changes two major levers:
- Direct diclofenac potassium amount: “containing diclofenac as 50 mg of diclofenac potassium” (not “not more than 50 mg”).
- Bicarbonate excipient flexibility: alkali metal bicarbonates or carbonates (or mixtures).
It also repeats:
- oral administration,
- alkali bicarbonates/carbonates present at 20 to 80% by weight based on weight of the acid form of diclofenac,
- dosage presentation as intact tablet or powder dissolved/dispersed in water.
Claims 12 and 13: tablet embodiment and reconstitution workflow
- Claim 12: tablet with 50 mg diclofenac potassium.
- Claim 13: before administration, provide unit dose powder of diclofenac potassium, dissolve/disperse in water.
Claims 14 and 15: liquid embodiment and salt/excipient specificity
- Claim 14: formulation is a liquid.
- Claim 15: sodium or potassium salt diclofenac with sodium or potassium bicarbonates, again with the same 20 to 80% w/w relative constraint.
What are the key claim elements you would map to enforceability: “treating pain,” “20–80% bicarbonate,” and “≤50 mg diclofenac potassium”?
From an enforcement and freedom-to-operate standpoint, the claim estate is dominated by three quantitative/structural gates:
| Claim gate |
Where it appears |
Scope effect |
Likely infringement question |
| Bicarbonate/carbonate at 20–80% w/w relative to diclofenac acid-form weight |
Claims 1, 11, 15 |
Narrows to formulations with very high base content |
Does accused product hit that exact ratio? How is the “acid-form” reference weight computed? |
| Diclofenac potassium amount constraint |
Claim 1: ≤50 mg; Claim 11: exactly 50 mg |
Narrows to dose size window |
Is the accused dose 50 mg (claim 11) or under 50 mg (claim 1) per unit? |
| Formulation presentation (intact tablet; powder dissolved/dispersed; dependent liquid claims) |
Claims 1, 11; plus dependent claims 3–4, 6–7, 8, 9, 12–14 |
Defines what product form is covered |
Is the product marketed as tablet vs mix-in powder vs liquid? |
The rest (alkali salt identity sodium/potassium; excipient identity potassium/sodium bicarbonate) further narrow dependent claim pathways.
How many distinct invention “bins” exist across these claims?
You can partition the claims into four enforceable “bins,” each with different practical targeting:
-
Bin A: Claim 1 composition geometry + ≤50 mg potassium
- diclofenac acid/salt + alkali bicarbonate (20–80% w/w relative) + tablet or reconstituted/dispersed powder
- potassium load capped at ≤50 mg equivalent
-
Bin B: Claim 11 fixed 50 mg potassium + bicarbonate/carbonate flexibility
- diclofenac potassium exactly 50 mg + alkali bicarbonate or carbonate (20–80% w/w relative) + tablet or reconstituted/dispersed powder
-
Bin C: Workflow bin (Claim 8 or 13 reconstitution step)
- supplies unit dose powder then dissolves/disperses in water prior to dosing
- applies even where the “final formulation” is created by the end user/consumer
-
Bin D: Liquid bin (Claims 9 and 14)
- expands target to liquid products under inherited quantitative constraints
What is the US patent landscape around US 7,482,377: how to locate upstream/downstream IP risk?
Because the user-supplied text provides only claim language and the patent number, a complete “landscape” (same-family claims, continuations, related US patents by other assignees, Orange Book entries, and active Paragraph IV litigation) cannot be reconstructed accurately without the patent’s bibliographic data (assignee, filing dates, publication, and cited references) and without an external query to USPTO/Orange Book/Pacer dockets.
No further landscape assertions are provided.
Which generics or “buffered diclofenac” formats could fall within this claim scope?
Even without a specific accused product, the claim language implies a tight mapping:
- Products with high-base loading: Any oral diclofenac formulation where alkali bicarbonate content is as high as 20–80% w/w relative to diclofenac acid-form weight is the primary candidate.
- Dose size sensitivity: If the product uses diclofenac potassium at 50 mg per unit, claim 11 is the most directly aligned. If it uses less than or equal to 50 mg, claim 1 is potentially aligned.
- Delivery form: Tablets and mix-in powder/dose forms align directly. Liquid forms are covered through dependent claims (9 and 14), assuming the inherited constraints are met.
- Salt identity: If diclofenac is sodium/potassium salt and bicarbonate/carbonate are sodium/potassium bases, dependent claims 2, 5, and 15 are the most natural read.
How strong is the patent estate for enforcing on formulation vs dosing method?
Based solely on claim scope:
- Formulation strength: High on quantification. The 20–80% w/w requirement is a clear technical parameter that can be tested analytically. This typically strengthens validity and infringement defensibility versus vague “buffering” language.
- Dosing-method strength: Medium. The “method of treating pain” framing plus oral administration is broad, but method claims often face challenges depending on proof of use. The added reconstitution step in claim 8/13 improves enforcement leverage against “powder to be dissolved in water” consumer workflows.
- Design-around pathways: Mainly through quantitative shift (outside 20–80% base loading), dose-size manipulation (above 50 mg potassium equivalent so claim 1 fails, or avoiding 50 mg so claim 11 fails), or changing excipient identity (using bases outside bicarbonates/carbonates for the specific dependent scope).
Key Takeaways
- US 7,482,377 covers oral methods of treating pain with diclofenac formulations that include alkali metal bicarbonates at 20–80% w/w relative to diclofenac acid-form weight.
- The claim set is anchored by dose constraints: ≤50 mg diclofenac potassium in claim 1 and exactly 50 mg diclofenac potassium in claim 11.
- Dosage forms covered include intact tablets and powder that is dissolved or dispersed in water; dependent claims add liquid embodiments and end-user reconstitution workflows.
- The most commercially actionable risk is for products that combine high base loading with diclofenac potassium at or near 50 mg per unit, especially where sodium/potassium bicarbonates are used.
FAQs
-
Does US 7,482,377 require bicarbonate, or can it be carbonate?
Bicarbonate is required in claim 1; claim 11 expands to bicarbonate or carbonate (or mixtures).
-
What is the significance of “20 to 80% by weight based on the weight of the acid form of diclofenac”?
It is the key quantitative limitation defining the base-to-diclofenac ratio and is central to infringement determination.
-
Can a product with 60 mg diclofenac potassium avoid claim 1?
Claim 1 limits diclofenac potassium to “not more than 50 mg,” so a 60 mg-per-dose product would not meet that specific constraint as written.
-
Is the reconstitution step part of the claims?
Yes, claim 8 and claim 13 add steps requiring providing a unit dose powder and dissolving/dispersing in water before administering.
-
Does the patent cover liquid diclofenac products?
Dependent claims 9 and 14 specify the formulation is a liquid, inheriting the main quantitative/structural limitations from the parent claims.
References (APA)
- Claims text provided in prompt for US Patent 7,482,377.
